Share on StockTwits
 

Analysts at Deutsche Bank upped their target price on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) to $410.00 in a research report issued to clients and investors on Tuesday, Stock Ratings News reports. Deutsche Bank’s price objective indicates a potential upside of 34.87% from the stock’s previous close.

A number of other firms have also recently commented on REGN. Analysts at TheStreet reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Buy” and a consensus target price of $307.84.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 6.05% during mid-day trading on Tuesday, hitting $322.38. 2,582,877 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a one year low of $154.16 and a one year high of $319.83. The stock has a 50-day moving average of $282.5 and a 200-day moving average of $279.8. The company has a market cap of $31.666 billion and a price-to-earnings ratio of 43.28.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings data on Tuesday, February 11th. The company reported $2.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.97 by $1.27. The company had revenue of $610.00 million for the quarter, compared to the consensus estimate of $579.17 million. During the same quarter in the previous year, the company posted $1.47 earnings per share. The company’s revenue for the quarter was up 47.0% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $3.91 EPS for the current fiscal year.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi acquired 168,511 shares of the company’s stock on the open market in a transaction that occurred on Friday, February 7th. The stock was purchased at an average cost of $286.78 per share, with a total value of $48,325,584.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.